Oncology Partnering Deals - 500 Beiträge pro Seite

[mulga]

Liebe aktive MediGene Gemeinde, liebe Leser,

die Spekulationen um einen MediGene EndoTAG-1 Deal laufen in den verschiedenen Threads auf Hochtouren. In diesem Thread will ich eine Liste von Partnerschaften der letzten Jahre im Bereich der Onkologie zusammenstellen.

Der besseren Übersicht wegen bitte ich Diskussionen zum Thema ausschließlich in den anderen Threads zu führen. Infos zu weiteren onkologischen Partnerschaften sind willkommen.

Die hier wiedergegebenen Verträge sind sicher nicht mit dem anstehenden EndoTAG-1 Deal vergleichbar. Dennoch bieten sie einen Überblick, was Pharmaunternehmen bereit sind, in die verschiedenen Entwicklungsphasen eines Medikaments oder in eine Medikamentenplattform kurzfristig bzw. bei erfolgreicher Entwicklung und Vermarktung langfristig zu investieren.

Intension dieses Threads ist, eine kompakte Zusammenfassung für spätere Vergleiche interessierten Lesern zur Verfügung zu stellen.
Spekulationen über den Aufbau eines Vertrags und über die mögliche Höhe von kurzfristigen und langfristigen Meilensteine sind näher an der Realität, wenn sie auf historischen Informationen aufbauen.

Viel Spaß beim Studieren wünscht euch euer

mulga

[mulga]

Übersicht:

M&A-Trends in der Pharma- und Biotech-Branche: Analyse eines Geschäftsmodells
http://www.innovations-report.de/html/berichte/studien/m_a_t…


Liste der aktivsten Dealmaker der letzen Jahre:

Pfizer, Roche, Novartis AG, Sanofi-Aventis, Schering Plough, Eli Lilly, Amgen, GlaxoSmithKline, Johnson & Johnson, Abbott, Astellas, AstraZeneca, Bayer Schering Pharma AG, Bristol-Myers Squibb, Merck & Co, Merck – Serono KgaA, Wyeth, Boehringer Ingelheim, Novo Nordisk, Daiichi Sankyo, Takeda, Teva, Eisai, Otsuka


Weniger aktive Unternehmen:

Actavis, Akzo Nobel, Alcon Labs, Allergan, Baxter International, Biogen Idec, Cephalon, Chugai, CSL, Dainippon Sumitomo, Forest Laboratories, Genzyme, Gilead Sciences, King, Lundbeck, Menarini, Mitsubishi, Nycomed Pharma, Procter & Gamble, Shionogi Seiyaku, Shire, Solvay, Tanabe Seiyaku, TAP Pharmaceuticals, UCB,Watson

 

[mulga]

GSK - Genmab
December 2006 - Phase III - $2,100m http://www.gsk.com/media/pressreleases/2006/2006_12_19_GSK94…

GlaxoSmithKline and Genmab announced a worldwide agreement to co-develop and commercialize HuMax-CD20 (ofatumumab).

Under the terms of the agreement, Genmab will receive a license fee of DKK 582 million (approximately $102 million), and GSK will invest DKK 2,033 million (approximately $357 million) to purchase, 4,471,202 ordinary shares of Genmab. The total potential value of this agreement, in the event of full commercial success, in cancer and various autoimmune and inflammatory diseases, could exceed DKK 12.0 billion (approximately $2.1 billion), including the initial license fee and equity purchase, milestone payments, totaling DKK 9.0 billion (approximately $ 1.6 billion) and expected development, commercial manufacturing and commercialization costs.

In addition, Genmab will be entitled to receive tiered double digit royalties on global sales of HuMax-CD20.

GSK will receive an exclusive worldwide license to HuMax-CD20 as well as any other antibodies with affinity for the CD20 antigen which Genmab may develop. GSK will also have an exclusive option to a CD20 UniBody to be developed in collaboration with Genmab. GSK and Genmab will co-develop HuMax-CD20. Genmab will be responsible for development costs until 2008, including costs of the two ongoing late stage oncology studies after which development costs will be shared equally between GSK and Genmab. GSK will be solely responsible for the manufacturing and commercialization of HuMax-CD20.

Genmab will have an option to co-promote HuMax-CD20 in a targeted oncology setting in the US and in the Nordic region. Should this be undertaken, Genmab will also have the option co-promote Bexxar and Arranon in the US and Atriance in the relevant countries of the Nordic region.

[mulga]

Novartis - Antisoma
April 2007 - Phase II - $890m http://www.antisoma.com/asm/media/press/pr2007/2007-04-19a/

Antisoma has signed an exclusive global licensing agreement with Novartis for its vascular disrupting agent AS1404 (DMXAA).

Antisoma will receive near-term payments of USD 100 million. $75 million will be paid immediately and a further $25 million when AS1404 enters a phase III trial in lung cancer.

Antisoma will be eligible for total upfront, development, regulatory and sales-related milestone payments of up to $890 million, contingent upon successful development and marketing of AS1404 in multiple indications, launch of back-up products in multiple indications, and achievement of sales milestones. Furthermore, if AS1404 is approved and commercialised, Antisoma will receive royalties on AS1404 sales and will have an option to co-commercialise AS1404 in the United States.

Novartis will fund and conduct all future development of AS1404, and will also fund the outstanding costs of the phase II trials currently being completed by Antisoma. The agreement also includes the potential for Novartis to fund certain of Antisoma’s commercialisation costs.

[mulga]

BMS - Adnexus
February 2007 - Discovery - $1,290m http://www.goodwinprocter.com/NewsEvents/News/Adnexus%20Ther…

Bristol-Myers Squibb and Adnexus Therapeutics announced a worldwide strategic alliance to discover, develop and commercialize Adnectin-based therapeutics for important oncology-related targets.

Under the terms of the agreement, Bristol-Myers Squibb will provide committed funds of approximately $30 million over the next three years to Adnexus, consisting of upfront and guaranteed research payments. Adnexus also is eligible to receive regulatory milestone payments of up to $210 million per product, as well as royalties on product sales and sales-based milestone payments

[mulga]

Sanofi-Aventis - Oxford Biomedica
March 2007 - - Phase II - $690m http://www.bionity.com/news/e/63209/

Oxford BioMedica and sanofi-aventis have entered into an exclusive global licensing agreement to develop and commercialise TroVax for the treatment and prevention of cancers.

Sanofi-aventis will pay Oxford BioMedica up to €518 million (~US$690 million) if all development and registration targets are met for certain defined indications. Additional payments will be made if regulatory milestones are achieved in other cancer types.

Oxford BioMedica will receive an initial payment of €29 million (~US$39 million) and further near-term payments of €19 million (~US$25 million) as milestones linked to the ongoing Phase III TRIST study in renal cancer.

Oxford BioMedica is also entitled to escalating royalties on global sales of TroVax and to further undisclosed commercial milestones when net sales of TroVax reach certain levels.

Oxford BioMedica has an option to develop TroVax for other cancer types in exchange for enhanced financial returns, and sanofi-aventis will keep all commercial rights.

Oxford BioMedica will supply TroVax to sanofi-aventis on commercial terms.

Oxford BioMedica and sanofi-aventis will co-fund the ongoing Phase III TRIST study of TroVax in renal cancer.
Sanofi-aventis will fund all future research, development, regulatory and commercialisation activities, including the immediate implementation of a development plan for TroVax in metastatic colorectal cancer.

Sanofi-aventis will be responsible for the global commercialisation of TroVax and will book the sales worldwide. Oxford BioMedica retains an option to participate in the promotion of TroVax in the United States and the European Union.
 

[mulga]

Merck & Co - ARIAD
July 2007 - Phase II - $1,130m http://www.medicalnewstoday.com/articles/76774.php

ARIAD Pharmaceuticals and Merck & Co have entered into a global collaboration to jointly develop and commercialize AP23573, ARIAD's novel mTOR inhibitor, for use in cancer.

The agreement provides for an initial payment of $75 million to ARIAD, up to $452 million more in milestone payments to ARIAD based on the successful development of AP23573 in multiple cancer indications (including $13.5 million for the initiation of the Phase III clinical trial in metastatic sarcomas and $114.5 million for the initiation of other Phase II and Phase III clinical trials), up to $200 million more based on achievement of significant sales thresholds, at least $200 million in estimated contributions by Merck to global development, up to $200 million in interest-bearing repayable development-cost advances from Merck to cover a portion of ARIAD's share of global-development costs (after ARIAD has paid $150 million in global development costs), and potential commercial returns from profit sharing in the U.S. or royalties paid by Merck outside the U.S

[mulga]

GSK - Synta
October 2007 - Phase III -: $1,100m http://findarticles.com/p/articles/mi_m0EIN/is_2007_Oct_10/a…

GlaxoSmithKline and Synta Pharmaceuticals announced the execution of a global collaboration agreement for the joint development and commercialization of STA-4783, a first-in-class, small-molecule, oxidative stress inducer that is entering Phase 3 clinical development for the treatment of metastatic melanoma.

Under the terms of the agreement, the companies will share responsibility for development and commercialization of STA-4783 in the U.S. and GSK will have exclusive responsibility for development and commercialization of STA-4783 outside the U.S.

Synta will receive an upfront cash payment of $80 million. Synta will also be eligible to receive potential milestone payments of up to $135 million for events leading to approval of STA-4783 in metastatic melanoma, further development and regulatory milestones of up to $450 million across various indications and up to $300 million in potential commercial milestone payments based on achieving certain net sales thresholds. Synta will continue to fund all development for metastatic melanoma in the U.S. and the companies will share responsibility and costs for development of STA-4783 in other indications.

Synta and GSK will jointly commercialize STA-4783 in the U.S. with Synta receiving a tiered profit share based on levels of annual net sales. The parties will share development costs outside of the U.S. and Synta will receive double-digit tiered royalties on net sales. In addition, GSK may, subject to Synta's agreement, purchase, up to $45 million of Synta's common stock upon the future achievement of specified development and regulatory milestones.

[mulga]

Celgene - Array
September 2007 - Cancer, Anti-inflammatory - Discovery - $1,050m http://www.fiercebiotech.com/press-releases/press-release-ar…

Under the agreement, Celgene will make an upfront payment of $40 million to Array, and, in return, Array will grant Celgene an option to select drugs developed under the collaboration that are directed to two of four mutually selected discovery targets.

Array will be responsible for all discovery and clinical development through Phase 1 or Phase 2a. At that time, Celgene will have the option to select drugs resulting from up to two of these four therapeutic programs and will receive exclusive worldwide rights to those drugs, except for Array's limited co-promotional rights in the U.S.

Additionally, Array is entitled to receive, for each drug, potential milestone payments of approximately $200 million, if certain discovery, development and regulatory milestones are achieved and $300 million if certain commercial milestones are achieved, as well as royalties on net sales. Array will retain all rights to the other programs.

[mulga]

GSK - OncoMed
December 2007 - Preclinical - $1,400m http://www.oncomed.com/news/pr/pr8.html

The alliance leverages OncoMed's expertise in the discovery and development of cancer stem cell antibody therapeutics and provides GSK with an option to license four product candidates directed at multiple cancer stem cell targets from OncoMed's broad library of monoclonal antibodies.

OncoMed will receive an undisclosed initial payment comprised of cash as well as an equity investment. In addition, OncoMed is eligible to earn milestone payments up to $1.4 billion from GSK based on the achievement of specified discovery, development, regulatory and commercial milestones.

OncoMed will also receive double-digit royalties on all collaboration product sales. Furthermore, GSK will have an option to invest in a future initial public offering by OncoMed

[mulga]

Celgene - Acceleron
February 2008 - Cancer, Metabolic - Phase I - $1,900m http://www.avalonvi.com/news_2008-02-28.html

The collaboration combines both companies’ resources and commitment to developing products for the treatment of cancer and cancer-related bone loss. In pre-clinical and early clinical studies, this innovative compound has reported success in key biomarkers of bone formation. The companies also signed an option agreement for certain discovery stage programs.

Under the terms of the agreement, Celgene and Acceleron will jointly develop, manufacture and commercialize Acceleron’s products for bone loss. Celgene will make an upfront payment to Acceleron of $50 million, which includes a $5 million equity investment in Acceleron. In addition, in the event of an initial public offering of Acceleron, Celgene will purchase a minimum of $7 million of Acceleron common stock.

[mulga]

Takeda - Amgen
February 2008 - Cancer, Inflammatory, Pain - Market - $900m http://www.takeda.com/press/article_28982.html

The collaboration includes early to mid-stage clinical-stage candidates across a range of therapeutic areas, including oncology, inflammation, and pain.

The financial terms include an upfront cash payment to Amgen of $200 million. Takeda will also pay to Amgen up to $340 million in expected worldwide development costs for these molecules over the next several years, $362 million in success-based milestone payments, and double digit royalties on sales in Japan. Additionally, Takeda plans to acquire all the shares of Amgen's Japanese subsidiary, Amgen KK. We anticipate the share transaction to close in the first quarter.

In addition, Takeda will become Amgen's worldwide partner for motesanib diphosphate (AMG 706), and will pay Amgen $100 million upfront, $175 million in success-based milestones for the first two indications, and double digit royalties on sales in Japan. Takeda will also pay 60 percent of ongoing clinical development expenses outside Japan and share potential profits outside Japan 50/50.

[mulga]

Sanofi-Aventis - Dyax
February 2008 -- Preclinic - $500m http://www.biospace.com/news_story.aspx?NewsEntityId=85741

Agreement in which sanofi-aventis has been granted an exclusive worldwide license for the development and commercialization of the fully human monoclonal antibody DX-2240, as well as a nonexclusive license to Dyax's proprietary antibody phage display technology.

Under the terms of the two agreements, Dyax is eligible to receive up to $500 million in license fees and milestone payments in the case of full commercial success of the first five antibody candidates, including DX-2240. Dyax will receive $25 million in 2008. In addition, Dyax is eligible to receive royalties based on commercial sales of DX-2240 and other antibodies developed by sanofi-aventis.

As exclusive licensee, sanofi-aventis will be responsible for the ongoing development, commercialization and consolidation of sales of DX-2240. For certain other future antibody product candidates discovered by sanofi-aventis, Dyax will retain co-development and profit sharing rights, while sanofi-aventis will maintain the leadership in development and commercialization, and book sales worldwide.

[mulga]

Kyowa Hakko - Amgen
March 2008 - Inflammation, Oncology - Phase I -: $520m http://findarticles.com/p/articles/mi_m0EIN/is_2008_March_6/…

Agreement under which Amgen will receive an exclusive license to develop and commercialize Kyowa Hakko's humanized monoclonal antibody KW-0761 worldwide, except in Japan, Korea, China and Taiwan. Kyowa Hakko will retain the development and commercialization rights in these countries.

Under the terms of the deal, Amgen will make an upfront payment to Kyowa Hakko of $100 million. Kyowa Hakko could receive up to $420 million in additional payments, including development, approval and sales milestones. Kyowa Hakko will also be entitled to receive double digit royalties on sales

[mulga]

Takeda - Alnylam
May 2008 - Cancer, Metabolic - Discovery - $1,000m http://phx.corporate-ir.net/phoenix.zhtml?c=148005&p=irol-ne…

This collaboration provides Takeda with broad, worldwide, non-exclusive access to and enablement with Alnylam's RNAi therapeutics platform technology and intellectual property in the fields of oncology and metabolic disease, with the right to expand the number of therapeutic fields in the future. The agreement also includes the transfer of platform technology from Alnylam to
Takeda, a collaboration and cross-license of delivery technologies between the two companies, and a drug discovery collaboration on certain RNAi therapeutic targets, subject to certain Alnylam third party obligations.

Takeda becomes Alnylam's strategic partner for RNAi therapeutics over a five-year period and the only Asian company to obtain a right of first negotiation to develop and commercialize Alnylam RNAi therapeutic development programs for the Asian market, excluding Alnylam's ALN-RSV01 program. In addition, Alnylam obtains opt-in options to co-develop and co-commercialize Takeda RNAi therapeutic programs in the U.S. market on a 50-50 basis.

The partnership includes $100 million in upfront payments and $50 million in near-term technology transfer payments for a non-exclusive license in two therapeutic fields and is valued at potentially over $1 billion in future research and development and commercial milestones, upon successful commercialization of multiple products. At Takeda's option, the scope of the partnership can be expanded to include additional fields with a $50 million per field expansion payment. Alnylam is also eligible to receive research and development funding related to the drug discovery collaboration. In addition, Alnylam is eligible to receive up to $171 million in development and commercial milestone payments and significant royalties per product

[mulga]

Roche - Thrombogenics
June 2008 -- Phase I - US$775m http://www.bioportfolio.com/biotech_news/BioInvent_28.htm

Under the terms of the agreement effective from June 17, 2008 (or if a U.S. anti-trust clearance is required, from the date of receipt of such clearance), Roche will pay BioInvent and ThromboGenics an upfront payment of €50 million. In addition, BioInvent and ThromboGenics could potentially receive up to €450 million over the term of the collaboration based on the successful completion of a series of development and commercial milestones for multiple indications, as well as double digit royalties on potential product sales, including any backup antibodies based on inhibition of PlGF. ThromboGenics, which discovered TB-403, will receive 60% and BioInvent 40% of the revenue from the deal. Roche will have a worldwide, exclusive license to develop and commercialize TB-403. BioInvent and ThromboGenics will retain co-promotion rights for the product in the Nordic, Baltic and Benelux regions.

BioInvent and ThromboGenics are responsible for any remaining costs associated with the recently completed Phase Ia trial in healthy volunteers. Roche will assume responsibility for all future development costs for this novel therapy, including the costs of the pending Phase Ib trial in patients to be run by BioInvent and ThromboGenics.

BioInvent and ThromboGenics in conjunction with Roche will form a Joint Steering Committee to oversee research and development activities. In addition, Roche will also provide funding to BioInvent and ThromboGenics for research on non-cancer indications and supply of clinical material until transfer of manufacturing.

[mulga]

BMS - PDL BioPharma
August 2008 - Phase I - US$710m http://www.genengnews.com/news/bnitem.aspx?name=40714870

Bristol-Myers Squibb would pay PDL BioPharma an upfront cash payment of $30 million for the development and marketing rights to elotuzumab and for an option to expand the collaboration to include PDL241, another anti-CS1 antibody, upon completion of pre-agreed preclinical studies. PDL BioPharma could receive additional payments of up to $480 million based on pre-defined development and regulatory milestones and up to $200 million based on pre-defined sales-based milestones for elotuzumab in multiple myeloma and other potential oncology indications.

The companies will share development costs, with Bristol-Myers Squibb providing 80 percent of the funding and PDL BioPharma providing 20 percent. Bristol-Myers Squibb will lead global development activities, and PDL BioPharma will complete the ongoing Phase I program and provide support for Phase II studies. The companies would share profits on sales of elozutumab in the U.S. PDL BioPharma would receive royalties on net sales of elotuzumab outside the U.S.

If Bristol-Myers Squibb exercises its option to expand the collaboration to include PDL241, PDL BioPharma would receive an additional cash payment of $15 million and could receive additional payments of up to $230 million based on pre-defined development and regulatory milestones and up to $200 million based on pre-defined sales-based milestones. The same division of development costs and profit sharing that apply to elotuzumab would apply to PDL241.

[mulga]

BMS - Exelixis
December 2008 - Phase I, III http://www.fiercebiotech.com/story/bms-pay-exelixis-240m-can…

Bristol-Myers Squibb agreed to pay Exelixis an upfront cash payment of $195 million for the development and commercialization rights to both programs and to make additional license payments of $45 million in 2009.

The companies have agreed to co-develop XL184. Exelixis will have the option to co-promote XL184 in the United States. The companies will share worldwide development costs and commercial profits on XL184 in the United States. Exelixis will be eligible to receive sales performance milestones of up to $150 million and double-digit royalties on sales outside the United States. The clinical development of XL184 will be directed by a joint committee. It is anticipated that Exelixis will conduct a significant portion of clinical development activities through 2010. Exelixis may opt out of the co-development of XL184, in which case Exelixis would instead be eligible to receive development and regulatory milestones of up to $295 million, double-digit royalties on XL184 product sales worldwide, and sales performance milestones.

Bristol-Myers Squibb will receive an exclusive worldwide license to develop and commercialize XL281 and will be responsible for funding all future development. Exelixis is eligible for development and regulatory milestones of up to $315 million, sales performance milestones of up to $150 million and double-digit royalties on worldwide sales of XL281.

[mulga]

GlobeImmune - Celgene
May 2009 - Preclinic, Phase I, Phase II - US$540m http://www.globeimmune.com/index.php?load=news&page=index&op…

GlobeImmune will receive a $40 million upfront payment from Celgene, which includes an equity investment in GlobeImmune. In return, GlobeImmune is granting Celgene an exclusive option to all oncology programs, including GI-4000, a Tarmogen technology-based product currently in phase II pancreatic cancer studies as well as all of GlobeImmune’s other oncology product candidates on a program by program basis. GlobeImmune will conduct the early development of the product candidates through certain pre-defined endpoints. Celgene will have the option to obtain an exclusive worldwide license to develop and commercialize these unique immunotherapy product candidates. GlobeImmune is eligible to receive over $500 million in development and regulatory milestones, double-digit royalties and additional milestone payments based on net sales of the licensed product candidates.

[mulga]

Genzyme - Bayer
March 2009 - CNS, Oncology - Phase III, Marketed - US$2,900m http://www.tradingmarkets.com/.site/news/Stock%20News/225297…

Agreement to acquire the worldwide rights to Campath® (alemtuzumab) from Bayer HealthCare, giving Genzyme primary responsibility for the development and commercialization of this potential break-though treatment for multiple sclerosis (MS). Bayer will continue to fund a portion of alemtuzumab’s development in MS and will retain an option to co-promote the product in MS upon approval. In addition, Genzyme will assume sole responsibility for worldwide sales and marketing for Campath in B-cell chronic lymphocytic leukemia (CLL), where it is indicated for use as a single agent in first-line and previously-treated patients with this disease. Bayer will retain the right to develop and commercialize alemtuzumab in solid organ transplant indications.

Bayer will receive payments based on revenues (subject to an aggregate cap) and potential milestone payments if cumulative revenue targets are achieved. There are no upfront payments for the rights of these three drugs. The transaction would provide Genzyme approximately $185 million in oncology revenue in 2009 and up to $700 million in revenue over the next three years. Genzyme’s Oncology segment revenues in 2008 were $117 million. Today’s announcement supports the company’s goal of 20 percent compound average non-GAAP earnings growth from 2006 to 2011.

[mulga]

Algeta - Bayer
September 2009 - Oncology Phase 3 since 2008_06_17 - US$800m http://www.algeta.com/xml_press_underside.asp?xml=http://cws…

Alpharadin (Radium-223)in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases

Algeta retains option for co-promotion and profit sharing in USA

Potential deal value of $800 million (€560m*) plus tiered double digit royalties. Algeta to receive $61 million (€42.5m) cash upfront, followed by development and sales milestones. Algeta retains option for co-promotion and profit-sharing in USA. Algeta and Bayer will jointly develop Alpharadin, with Bayer contributing a substantial majority of the costs of future development.

Under the terms of the agreement, Algeta has an option for up to 50% co-promotion with Bayer in the United States under a profit-share arrangement. Bayer will commercialize Alpharadin globally and pay tiered double-digit royalties on net sales in markets where there is no co-promotion.

Bayer will also contribute a substantial majority of the costs of future development of Alpharadin as a treatment for bone metastases resulting from HRPC and from other cancer indications, and will fully fund any additional late-stage trials.

Danke an Sehnix!
Geht doch, auch in Krisenzeiten!

[Oberlaendler]

Hallo mulga,
schon etwas älter, wurde aber glaube ich noch nicht gepostet.

http://agn.client.shareholder.com/releasedetail.cfm?ReleaseI…
Allergan - Spectrum Pharmaceuticals

IRVINE, Calif., Oct 29, 2008 (BUSINESS WIRE) -- --Spectrum to Receive $41.5 Million at Closing and up to $304 Million in Milestone Payments
...
Spectrum is currently conducting two Phase 3 clinical trials to explore apaziquone's safety and efficacy as a potential treatment for non-muscle invasive bladder cancer following surgery. Spectrum expects to complete enrollment by year-end 2009.

Under the terms of the agreement, Allergan will pay Spectrum $41.5 million at closing and will make additional payments of up to $304 million based on the achievement of certain development, regulatory and commercialization milestones. Spectrum retained exclusive rights to apaziquone in Asia, including Japan and China. Allergan received exclusive rights to apaziquone for the treatment of bladder cancer in the rest of the world, including the United States, Canada and Europe. In the United States, Allergan and Spectrum will co-promote apaziquone and share in its profits and expenses. Allergan will also pay Spectrum royalties on all of its apaziquone sales outside of the United States. Spectrum will continue to conduct the apaziquone clinical trials pursuant to a joint development plan, with Allergan bearing the majority of these expenses.
...

Gruß Oberländler

[RichyBerlin]

Antwort auf Beitrag Nr.: 37.507.401 von mulga am 02.07.09 14:39:04

Wichtiger Nachtrag zu Beitrag #8
Geplatzt ! Auch das gibt es

Jun 15 2009, 11:07 AM EST
GSK Nixes $1B Cancer Deal with Synta

GlaxoSmithKline (GSK) decided to terminate its collaboration with Synta Pharmaceuticals since clinical trials with the compound being jointly developed were previously stopped due to safety concerns.

The deal, which had a $1 billion potential, earned Synta $130 million. Worldwide rights to elesclomol will revert to Synta, which may pay GSK a low single-digit royalty on any potential future sales of elesclomol.

At this point, however, Synta seems unlikely to continue developing the candidate, because initial Phase III data from a melanoma study showed more deaths in the treatment arm compared to controls. The news hit the company hard, and its stock spiraled down 77%, and Synta was forced to cut 40% of its staff....

http://www.genengnews.com/news/bnitem.aspx?name=56331875&sou…

[mig33]

ist zwar kein onkologie deal, aber zeigt auf, wie hoch es gehen kann. ist auch deshalb ganz gut vergleichbar, weil das produkt auch die phase 2 abgeschlossen hat u. vor dem eintritt in phase 3 steht!
------------------------------------------------------------

LONDON and SAN CARLOS, Calif., Sept 21, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- AstraZeneca and Nektar Therapeutics announced today that they have entered into an exclusive worldwide license agreement for two drug development programmes: NKTR-118, a late stage investigational product being evaluated for the treatment of opioid-induced constipation, and the NKTR-119 programme, an early stage programme that is intended to deliver products for the treatment of pain without constipation side effects. Both programmes were developed by Nektar, utilizing their proprietary small molecule advanced polymer conjugate technology platform.

Under the terms of the agreement, AstraZeneca will assume the responsibility for the continued development of both the NKTR-118 and NKTR-119 programmes, including the initiation of late-stage clinical studies for NKTR-118. AstraZeneca expects completion of the design of the phase III programme in the near term, and anticipates filing the drug with regulators in 2013. AstraZeneca will also be responsible for global manufacturing and marketing for both programmes. Under the agreement, Nektar will receive an upfront payment of $125 million for both NKTR-118 and NKTR-119.

NKTR-118 has completed a Phase 2 clinical trial and is being developed to treat constipation caused by the use of opioid pain products. Under the agreement, for NKTR-118, Nektar is eligible to receive up to $235 million in aggregate payments upon the achievement of certain regulatory milestones, as well as additional tiered sales milestone payments of up to $375 million if the product achieves considerable levels of commercial success. Nektar will also be eligible to receive significant double-digit royalty payments on net sales of NKTR-118 worldwide.
NKTR-119 is an early stage drug development programme that is intended to combine oral NKTR-118 with selected opioids, with the goal of treating pain without the side effect of constipation traditionally associated with opioid therapy. AstraZeneca will continue the development of this programme, including determining the appropriate opioid combinations with NKTR-118. For NKTR-119, Nektar would receive development milestone payments as well as tiered sales milestone payments. Nektar will also receive significant double-digit royalty payments on NKTR-119 net sales worldwide.

http://ir.nektar.com/releasedetail.cfm?ReleaseID=410294

[RichyBerlin]

Onyx strikes $851M deal to buy Proteolix
October 12, 2009 — 7:28am ET
By John Carroll
Onyx Pharmaceuticals (ONXX) has struck a deal to buy the cancer drug developer Proteolix for $276 million down and up to $575 million more for development and regulatory milestones. Included in the prospective payments is a whopping $170 million for the accelerated approval of its lead drug, a mid-stage therapy for multiple myeloma.

"It's a perfect fit with Onyx. We're successful in developing, they are successful in discovery. We can help them with development," Onyx CEO Tony Coles told Reuters. "We have been monitoring a number of oncology compounds over the past year. Proteolix is the right fit."

The spotlight at Proteolix has been focused on carfilzomib, a cancer drug now in a 250-patient Phase IIb trial which should deliver data next year. And the developer says that it expects to get the drug into a combo Phase III study next year, studying a concoction that will include Revlimid and the anti-inflammatory dexamethasone.

Onyx is flush with cash from sales of Nexavar, which may achieve blockbuster status next year. Coles says that he believes that carfilzomib may hit the same pace eventually. Carfilzomib is in a new class of proteasome inhibitors. "Treatment options in multiple myeloma have historically been limited, and there is a tremendous need to expand the treatment paradigm with agents offering an improved efficacy and safety profile," said Michael Kauffman, M.D., Ph.D., chief medical officer at Proteolix.

http://www.fiercebiotech.com/story/onyx-strikes-811m-deal-bu…

[RichyBerlin]

Medivation forges $765M cancer deal with Astellas
October 27, 2009 — 8:28am ET | By John Carroll

In just the latest sign of just how hot new cancer drugs have become, San Francisco-based Medivation garnered a $110 million upfront payment and a milestone package of $655 million from Astellas for global rights to its experimental prostate cancer drug. The therapy, MDV3100, is currently being evaluated in the Phase III AFFIRM clinical trial in men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy.

Medivation also gets a co-promotion deal in the U.S. market, a collaborator to help foot development costs and a partner who will provide royalties for sales outside the United States. "Astellas is the second major collaboration we have completed in the past year, and we are confident we have the right partners in place for each of our late-stage programs--Astellas for MDV3100 and Pfizer for Dimebon," said David Hung, M.D., president and chief executive officer of Medivation.

http://www.fiercebiotech.com/story/breaking-news-medivation-…

(Kommentare bitte in anderen Threads!)

[gnomli]

nicht oncology - rheumat Arthritis;

http://www.thestreet.com/_yahoo/story/10624515/1/bristol-lic…

[RichyBerlin]

Clavis inks $380M deal with Clovis Oncology
By Maureen Martino
24.11.09

Norway's Clavis Pharma has reason to celebrate this morning. The developer has inked a $380 million deal with US-based Clovis Oncology, sending shares up as much as 60 percent, according to Reuters. Clavis will get $15 million up front for CP-4126, a pancreatic cancer drug currently in Phase II trials. The remaining $365 million payout will come in stages and if the drug is approved, Clavis will receive tiered double-digit royalties on sales.

Clovis will take over all development of CP-4126 and will be responsible for commercializing the drug in the U.S., Europe, Canada, Central and South America. Clavis retains an option to co-promote and share profits in Europe. Additionally, the two drugmakers will work together to develop a companion diagnostic test to identify patients most likely to benefit from CP-4126.

Clovis, a 2009 Fierce 15 winner, raised a whopping $145 million in venture capital earlier this year. Its management team has been looking for drug developers willing to trade their promising oncology program for a chunk of money.

http://www.fiercebiotech.com/story/clavis-inks-380m-deal-clo…

[aufgepasst]

Novartis gains rights to two oral targeted investigational therapies focusing on patients with life-threatening blood disorders and cancers

Ex-US rights acquired for JAK inhibitor INCB18424 in Phase III development as first-in-class treatment for myelofibrosis, a life-threatening blood disorder * Global rights acquired for early-stage cMET inhibitor INCB28060 targeting tumor invasion and drug resistance in certain cancers including gastric, kidney and lung * Novartis to make payments of USD 150 million upfront and first milestone of USD 60 million; Incyte eligible for milestone payments and royalties on future sales Basel, November 25, 2009 - Novartis has gained exclusive rights to two oral targeted investigational therapies for patients with a range of life-threatening blood disorders and cancers that currently do not have effective treatment options. Under a licensing agreement with Incyte Corporation, Novartis will have responsibility for the future development of Incyte's investigational JAK inhibitor outside the US and for future development of an early-stage cmet inhibitor globally. * The lead compound is a Janus kinase (JAK) inhibitor with the investigational name INCB18424. This oral targeted therapy is in Phase III clinical trials for the treatment of myelofibrosis, a life-threatening neoplastic condition with no effective medical treatment[1] that is characterized by varying degrees of bone marrow failure, splenomegaly (enlarged spleen) and debilitating symptoms. INCB18424 has the potential of becoming a first-in-class therapeutic agent for the treatment of this and other hematologic diseases. * The second compound covered in the licensing agreement, a mesenchymal-epithelial transition factor kinase (cMET) inhibitor with the investigational name INCB28060, is entering Phase I development. Compounds in this class are envisioned to become effective cancer therapies through their ability to block molecular signals leading to tumor cell angiogenesis, proliferation, survival, invasion and metastasis. Multiple cancers have shown to be dependent on activation of molecular signals by genetic alterations of the cMET gene[2]. Emerging evidence indicates that cMET inhibition may be useful in the treatment of certain cancers, including gastric and kidney cancer[2], and may help to overcome resistance to some targeted therapies, such as gefitinib in non-small cell lung cancer[3]. "A key Novartis priority is to bring innovative medicines to patients as quickly as possible," said David Epstein, President and CEO, Novartis Oncology and Novartis Molecular Diagnostics. "This agreement leverages these two promising investigational drugs with Novartis Oncology's global development and commercialization expertise and our wide range of multi-targeted approaches to cancer treatment." Terms of the agreement Novartis will make an upfront payment of USD 150 million to Incyte and a first milestone payment of USD 60 million for initiation of the European Phase III trial of the JAK inhibitor INCB18424 that began in July of this year. The agreement covers ex-US commercialization rights for the JAK inhibitor and global commercialization rights for the cMET inhibitor INCB28060. Each company will be responsible for costs in their respective territories for the JAK inhibitor, with costs of collaborative studies shared equally. Novartis will be responsible for all costs and activities for the cMET inhibitor after the Phase I clinical trial. After the first milestone, Incyte will be eligible for additional payments based on achieving defined development and commercialization milestones and to receive royalties on future sales. Incyte also has an option to co-promote the cMET inhibitor in the US and to participate in the cMET inhibitor's global development.

http://aktien.onvista.de/news-filter.html?ID_OSI=90609

[mig33]

Novartis to Develop and Commercialize Incyte’s Lead JAK1/JAK2 Inhibitor, INCB18424, for Territories Outside the US and Incyte’s cMET Inhibitor, INCB28060, Worldwide

Incyte May Receive Over $1 Billion in Payments, Including $150 Million Upfront Plus an Immediate $60 Million Development Milestone in Addition to Future Potential Milestones and Royalties

http://investor.incyte.com/phoenix.zhtml?c=69764&p=irol-news…

[RichyBerlin]

Spectrum adds to cancer pipeline with $350M deal
February 2, 2010 — 8:31am ET | By John Carroll

Spectrum Pharmaceuticals is paying $30 million down and up to $320 million in cash and a million shares of stock for a significant share of the worldwide rights to a late-stage cancer compound advanced by TopoTarget A/S.
Spectrum (SPPI) is putting up the money in exchange for the North American and Indian rights to Belinostat, an HDAC inhibitor currently in a registrational trial for relapsed or refractory Peripheral T-Cell Lymphoma. The drug has been granted orphan drug and fast track designation by the FDA.

"With this collaboration, we have now completed our strategic initiatives relating to in-licensing of compounds with near term commercialization opportunities," says Spectrum CEO Rajesh Shrotriya, MD. "Belinostat's current registrational program is comprehensive and focused in that it targets key hematological indications such as PTCL and other solid tumor indications. Belinostat has the potential to be a best-in-class HDAC inhibitor for both hematological and solid tumors."

Spectrum, which also took an option on the Chinese market, is paying for 70 percent of the clinical trial costs while TopoTarget stands to earn double-digit royalties on any sales.
http://www.fiercebiotech.com/story/spectrum-adds-cancer-pipe…

[mulga]

Teva Expands Cancer Portfolio
By Zacks Equity Research , On Monday December 28, 2009, 11:12 am EST

http://finance.yahoo.com/news/Teva-Expands-Cancer-zacks-2993…

Teva will make an initial cash payment of $60 million to OncoGenex. This includes a $10 million equity investment in OncoGenex common stock, an upfront payment of $20 million and prepayment of $30 million for OncoGenex’ contribution to the development costs of OGX-011. Teva will also pay up to $370 million on the achievement of development and commercial milestones. Additionally, Teva will pay tiered royalties in the mid-teens to mid-twenties range on product sales. While Teva will be responsible for all commercialization and development expenses, OncoGenex has retained the option to co-promote OGX-011 in the U.S. and Canada.

[RichyBerlin]

Abbott buys Facet Biotech for $450M
By Maureen Martino
Abbott has succeeded where Biogen Idec once failed. The company announced late Tuesday that it's purchasing Facet Biotech for $450 million, or $27 a share. That's 67 percent premium over the biotech's closing price of $16.21 earlier today.

Abbott says the acquisition will boost its early- and mid-stage pharmaceutical pipeline. The developer has its eyes on two primary therapeutic areas--immunology and oncology.
The highest-priority program is daclizumab, a Phase II biologic for multiple sclerosis that will move into Phase III trials in Q2 of 2010. Facet is already partnered with Biogen Idec on the compound. The biotech also has oncology compounds for multiple myeloma and chronic lymphocytic leukemia in early to mid-stage trials...
http://www.fiercebiotech.com/story/breaking-news-abbott-buys…

[RichyBerlin]

Novartis offers $955M deal to snare Transgene drug option
By John Carroll
Novartis has put up $10 million and promised up to €700 million more in milestones in exchange for an option on Transgene's promising, late-stage cancer immunotherapy.

France's Transgene will hold on to control of the upcoming Phase IIb/III pivotal trial of TG4010 that is slated to get under way by the end of this year after enrolling about a thousand patients with non-small cell lung cancer.
Once Novartis gets its hands on the IIb portion of the data, the pharma giant will have 90 days to decide whether it will exercise its option on the program. The data is scheduled to arrive in early 2012.

If Novartis decides to pull the trigger on the option--a deal structure that is growing increasingly common in drug development--Transgene will get a fee plus milestones along with co-promotion rights in a list of countries that includes France and China. Novartis will gain control of the program and take responsibility for further costs...

..shares in the French biotechnology company went down 12 percent..
http://www.fiercebiotech.com/story/novartis-offers-955m-deal…

[gnomli]

nicht der beste deal, aber immerhin ein plattform-deal

http://finance.yahoo.com/news/Isis-Pharma-and-Glaxo-in-15B-a…

[mehrdiegern]

Antwort auf Beitrag Nr.: 39.257.123 von gnomli am 31.03.10 18:55:41

hängt ja auch vom marktpotential ab (kenne ich hier nicht)

gruß
mehdi

[RBW]

Merck takes control of Ariad cancer program in $583M deal
By John Carroll

Merck has opted to move into the driver's seat to steer the development of Ariad's late-stage cancer therapy ridaforolimus. The pharma company (ARIA) is taking direct control over the clinical development of the drug, paying Cambridge, MA-based Ariad $50 million upfront along with $19 million to reimburse the biotech for its R&D expenses to date and a reconfigured $514 million in regulatory and sales milestones.

Ridaforolimus is an mTOR inhibitor now in Phase III for advanced sarcomas. And the deal appears to mark a significant change for Ariad's business plan, which had included building a sales force around the launch of its first cancer drug. In a press conference this morning, Ariad CEO Harvey J. Berger, M.D. noted that the biotech company is retaining an option to handle 25 percent of the marketing work in the U.S., which allows the developer to get involved in commercialization work at a lower cost than it had expected earlier. Merck has already paid Ariad more than $125 million for its work developing the therapy.

Ariad's milestone package includes $25 million for acceptance of the new drug application by the FDA, $25 million for U.S. marketing approval, $10 million for European marketing approval, $5 million for Japanese marketing approval and $200 million in milestones based on achievement of "significant sales thresholds." Ariad also stands to gain tiered double-digit royalties from sales.

For Ariad, the shift in control gives the developer a chance to pivot to other prospects. "This will allow us to focus our resources on commencing the pivotal trial for our next promising product candidate - AP24534 - our investigational pan BCR-ABL inhibitor and on advancing development of AP26113 - our investigational ALK inhibitor," said Berger.
http://www.fiercebiotech.com/story/merck-takes-control-ariad…

[Soederbaum]

Astellas bid on OS

Astellas stellt sich mit einer Onkologie Pipeline durch den OSI deal weiter auf;

http://www.businessweek.com/news/2010-05-18/astellas-offer-o…

May 17 (Bloomberg) -- Astellas Pharma Inc. ended its two- month pursuit of OSI Pharmaceuticals Inc. after raising its initially hostile bid 11 percent to $4 billion to gain a U.S. sales force for oncology drugs.
The revised offer of $57.50 a share is 55 percent more than OSI’s price on Feb. 26, before Tokyo-based Astellas announced its hostile takeover, the companies said in a statement today. Both boards approved the new bid, which is 3.8 percent less than Melville, New York-based OSI’s closing price on May 14.
....
Adding OSI’s cancer treatments including Tarceva will help buffer the impact of competition from cheaper generic medicines that the company said last week will cause profit to slide for a third straight year.
“This is a step into the U.S., and into oncology,” said Jason Zhang, an analyst for BMO Capital Markets in New York, in a telephone interview. “I think this is good for them.”

Astellas joins Japanese rivals Takeda Pharmaceutical Co. and Eisai Co. in multibillion-dollar acquisitions in the past three years to expand in the U.S., the world’s largest drug market. Takeda, based in Osaka, bought Millennium Pharmaceuticals Inc. for $8.9 billion and Tokyo-based Eisai purchased MGI Pharma Inc. for $3.9 billion in 2008.

Prograf has faced generic competition since August, and Flomax, also known as Harnal, since March this year. Astellas has committed to spending more than $1 billion since October 2009 to gain rights to experimental treatments for cancer.


OSI earned operating income of $153 million and revenue of $428 million last year. Astellas’s revised bid amounts to about eight times OSI’s estimated 2010 revenue, according to data compiled by Bloomberg.
Takeda paid 13.5 times revenue for Millennium, OSI Chairman Robert Ingram and Chief Executive Officer Colin Goddard said in a March 15 letter to shareholders. Eli Lilly & Co. of Indianapolis paid 7.8 times revenue for ImClone Systems Inc. in 2008, they said.
Tarceva, OSI’s biggest drug, is a treatment for advanced non-small-cell lung cancer and pancreatic tumors. The company projected this year that Tarceva will have $7 billion in revenue through 2020. The drug generated $1.6 billion for OSI and its Basel, Switzerland-based partner Roche Holding AG last year.

[RBW]

Clovis teams up with Avila on $209M lung cancer deal
By John Carroll
Avila Therapeutics won an admirer and a collaborator when it inked a $209 million deal to partner up on one of its covalent drug programs with Clovis Oncology, a start-up backed with some serious cash and headed by an experienced crew of biotech players.

Boulder, CO-based Clovis agreed to pay an unspecified upfront and a slate of regulatory and sales milestones that add up to the $209 million total. And Clovis steps in to collaborate on the preclinical development of an Avila program for non small-cell lung cancer. The program--which Waltham, MA-based Avila is promising has unique covalent bonding ability--targets the T790M mutant form of the EGFR associated with resistance to Tarceva and Iressa, as well as targeting the initial activating EGFR mutations.

"We plan to file an IND as rapidly as possible and initiate an accelerated clinical development program, including the use of a companion diagnostic to identify patients with NSCLC who possess the T790M mutation," said Clovis CEO Patrick J. Mahaffy. "We believe that this program has the potential to meaningfully improve outcomes in patients with EGFR-mediated non-small cell lung cancer."

Clovis, a 2009 Fierce 15 company, launched with $145 million in venture backing, a sign of respect for a biotech team that built Pharmion and sold it for $2.9 billion.

Clovis, a 2009 Fierce 15 company, launched with $145 million in venture backing, a sign of respect for a biotech team that built Pharmion and sold it for $2.9 billion.
http://www.fiercebiotech.com/story/clovis-teams-avila-209m-l…" target="_blank" rel="nofollow ugc noopener">Clovis teams up with Avila on $209M lung cancer deal
By John Carroll Comment | Forward | Twitter | Facebook | LinkedIn
Avila Therapeutics won an admirer and a collaborator when it inked a $209 million deal to partner up on one of its covalent drug programs with Clovis Oncology, a start-up backed with some serious cash and headed by an experienced crew of biotech players.

Boulder, CO-based Clovis agreed to pay an unspecified upfront and a slate of regulatory and sales milestones that add up to the $209 million total. And Clovis steps in to collaborate on the preclinical development of an Avila program for non small-cell lung cancer. The program--which Waltham, MA-based Avila is promising has unique covalent bonding ability--targets the T790M mutant form of the EGFR associated with resistance to Tarceva and Iressa, as well as targeting the initial activating EGFR mutations.

"We plan to file an IND as rapidly as possible and initiate an accelerated clinical development program, including the use of a companion diagnostic to identify patients with NSCLC who possess the T790M mutation," said Clovis CEO Patrick J. Mahaffy. "We believe that this program has the potential to meaningfully improve outcomes in patients with EGFR-mediated non-small cell lung cancer."

Clovis, a 2009 Fierce 15 company, launched with $145 million in venture backing, a sign of respect for a biotech team that built Pharmion and sold it for $2.9 billion.
http://www.fiercebiotech.com/story/clovis-teams-avila-209m-l…

[RBW]

Sanofi inks $398M cancer R&D deal with Ascenta
By Maureen Martino

Sanofi-Aventis (NYSE: SNY) will pay up to $398 million for the rights to several of Ascenta Therapeutics' early-stage oral drug candidates. The French biotech will gain access to MI-773 and MI-519-64, Ascenta's two most advanced drug candidates, which are expected to begin preclinical development later this year. The early-stage targets are being investigated for their potential to restore tumor cell apoptosis, or programmed cell death. According to Ascenta's statement on the deal, the experimental drugs inhibit the interaction between HDM2 (Human Double Minute 2) and p53, which could enhance cancer control and treatment.

Under the terms of the deal, Sanofi will gain an exclusive worldwide license to develop, manufacture, and commercialize all program compounds. Ascenta gets an undisclosed upfront payment, as well as development, regulatory and commercial milestone payments that could total $398 million. The developer is also eligible for royalties on drug sales.

"Ascenta's mission since its founding has been to discover and develop novel small molecules that can trigger apoptosis in cancer cells. Sanofi-aventis has a great record of bringing innovative cancer therapies like these to cancer patients around the world," says Mel Sorensen, president and CEO of Ascenta. "Restoring tumor suppressor function through the inhibition of the HDM2-p53 interaction offers the potential to control and prevent cancer progression."
http://www.fiercebiotech.com/story/sanofi-inks-398m-cancer-r…

[Soederbaum]

OncoMed scores big cancer development pact with Bayer
June 17, 2010 — 11:23am ET
Germany's Bayer Schering is paying OncoMed $40 million upfront to partner on a slate of new drugs that target cancer stem cells. And the German pharma company is reserving an option to buy up to five programs through Phase I, with OncoMed in line to receive up to $387.5 million for each new biologic and $112 million for each small molecule drug that works its way to an approval.

The Redwood City, CA-based OncoMed also stands to earn double-digit royalties on any approved therapies, making this a foundation partnership to build a much bigger biotech company on--if it's successful. For Bayer, which already markets Nexavar and has late-stage drugs in development, the OncoMed programs represent an early-stage generation of promising oncology drugs to feed into the pipeline.

"The development of anti-cancer stem cell therapeutics together with OncoMed is a highly innovative approach with the potential to perfectly complement our oncology portfolio," said Prof. Andreas Busch, head of Global Drug Discovery at Bayer. "Anti-cancer stem cell research could turn out as one of the missing pieces in today's cancer therapy."

Bayer will take over the development of any therapy that it options from OncoMed. The agreement also contains "provisions under which OncoMed may co-develop biologic therapeutics with Bayer. The collaboration includes for example OncoMed's lead Wnt pathway antibody, [OMP-18R5], which is intended to enter clinical testing in 2011."

Read more: OncoMed scores big cancer development pact with Bayer - FierceBiotech http://www.fiercebiotech.com/story/oncomed-scores-big-cancer…
Subscribe: http://www.fiercebiotech.com/signup?sourceform=Viral-Tynt-Fi…

[RichyBerlin]

Seattle Genetics scores $900M cancer pact with Genentech
August 3, 2010 — 10:36am ET | By John Carroll

Genentech has anted up $12 million to expand its development pact for Seattle Genetics' antibody-drug conjugate (ADC) technology. And the Seattle biotech will now be able to play for a pot of cash that could swell to $900 million in fees and milestones.

Genentech has already shelled out $30 million to Seattle Genetics over the past eight years. Impressed by the technology's ability to match a tumor-targeting antibody with a cancer-killing toxin, Genentech now wants to expand its group of antigen targets. And in addition to the potential haul of fees and milestones--contingent on the commercialization of all the therapies covered in the expanded pact--Seattle Genetics can earn mid-single digit royalties on any products.

"We believe ADCs will play an important role in the future of cancer therapy. Genentech is committed to exploring the therapeutic potential of ADCs in a variety of hematologic malignancies and solid tumors," said James Sabry, vice president for Genentech Partnering. So far Seattle Genetics has banked $130 million from all the development pacts it has signed over the years. ...
http://www.fiercebiotech.com/story/seattle-genetics-scores-9…

[Oberlaendler]

Onyx Pharmaceuticals Announces Carfilzomib Development and Commercialization Agreement with Ono Pharmaceutical for Japan

Transaction Valued at More than $300 Million; Includes Anticancer Compounds Carfilzomib and ONX 0912

EMERYVILLE, Calif., Sept. 8 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it has entered into an exclusive agreement with Ono Pharmaceutical Co., Ltd. to develop and commercialize two compounds from Onyx's proteasome inhibitor development program, carfilzomib and ONX 0912. Under the terms of the agreement, Ono has exclusive rights to develop and commercialize both compounds for all oncology indications in Japan. Onyx retains commercialization rights in other countries in the Asia Pacific region, as well as in all other regions of the world, including the U.S. and Europe. The potential value of the transaction, which includes rights to all oncology indications for the two molecules, is estimated to exceed $300 million, plus royalties.

Carfilzomib, a highly selective proteasome inhibitor, is currently being evaluated in multiple clinical trials for the treatment of patients with multiple myeloma and other cancers. ONX 0912, an oral proteasome inhibitor, is currently in Phase 1 testing.

Ono will pay Onyx an upfront payment of Yen 5 billion (Japanese yen, approximately $59 million at current exchange rates). In addition, Onyx will receive development and sales-based payments related to the compounds that could total up to approximately $280 million at current exchange rates. The agreement also calls for royalty payments in double-digit percentages on net sales in Japan, commensurate with a late-stage asset.

"This strategically important transaction underscores the growing interest and excitement surrounding carfilzomib. Ono is an ideal partner in Japan given their focus on highly innovative new pharmaceutical products and their reputation for scientific excellence," said N. Anthony Coles, M.D., president and chief executive officer of Onyx. "Onyx is committed to reaching all patients with multiple myeloma who could potentially benefit from promising therapies such as carfilzomib and ONX 0912, as quickly as possible. This partnership allows us to benefit from Ono's drug development experience in Japan for the advancement of carfilzomib, while we focus on execution in the U.S. and Europe."

In the U.S., Onyx is preparing a new drug application (NDA) for carfilzomib, which it expects to submit to the Food and Drug Administration (FDA) by year-end 2010 for potential accelerated approval. Given this potential timeline, Onyx is engaged in planning and executing prelaunch activities.

"Ono is actively engaged in the development and the commercialization of innovative drugs in cancer and related areas, including Emend® for chemotherapy-induced nausea and vomiting and an antibody anticancer drug, as well as drugs for cancer anorexia / cachexia and for opioid-induced constipation, and recognizes the tremendous need for new treatment options for multiple myeloma. This agreement facilitates Ono's strategic expansion of its development pipeline in the oncology area with these exciting new compounds from a proven class of drugs. The promising activity and tolerability observed to date indicate that carfilzomib may be an important new treatment option for myeloma patients, and we look forward to collaborating with Onyx to bring this drug to patients in Japan," said Gyo Sagara, Ono's president, representative director and chief executive officer.

About the Proteasome Inhibitor Development Program

The proteasome has been validated as an important clinical target in cancer, and Onyx is developing next-generation proteasome inhibitors with a high degree of selectivity, with the goal of increasing therapeutic efficacy and reducing side effects.

The lead product candidate in this program is carfilzomib. Carfilzomib, a highly selective proteasome inhibitor, has shown encouraging results in a broad clinical trial program in multiple myeloma. Onyx recently announced top-line results from the Phase 2b 003-A1 study of single-agent carfilzomib in heavily pretreated patients with relapsed and refractory multiple myeloma, in which carfilzomib achieved an overall response rate (partial response or greater) of 24 percent and a median duration of response of more than seven months in patients who entered the study after receiving a median five prior lines of therapy (corresponding to a median of 13 anti-myeloma agents) and whose disease was refractory to their last therapeutic regimen.

Onyx has also initiated a large randomized international Phase 3 clinical trial, known as the ASPIRE trial, studying the combination of carfilzomib, lenalidomide, and low-dose dexamethasone in patients with relapsed multiple myeloma. The company has an agreement with the U.S. FDA on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMA) on the design and planned analysis for the ASPIRE trial. An additional Phase 3 clinical trial, known as the FOCUS trial, is planned to evaluate carfilzomib in patients with advanced myeloma and serve as the basis for a European registration. Carfilzomib is also being studied in advanced solid tumors.

ONX 0912 is distinct from carfilzomib, although the compound is based on the same chemistry that is employed to selectively target the proteasome. Upon completion of the current Phase 1 study in advanced refractory or recurrent solid tumors, Onyx expects that it will explore ONX 0912 in hematologic malignancies.

The development program also includes ONX 0914, an immunoproteasome inhibitor with activity in preclinical models of autoimmune disorders.

About Multiple Myeloma

Multiple myeloma is the second most common hematologic cancer and results from an abnormality of plasma cells, usually in the bone marrow. Worldwide, more than 180,000 people are living with multiple myeloma and approximately 86,000 new cases are diagnosed annually.(i) In Asia, there are approximately 28,000 people living with multiple myeloma (ii), including approximately 13,000 people living with multiple myeloma in Japan.(iii) In the United States, more than 50,000 people are living with multiple myeloma and approximately 20,000 new cases are diagnosed annually.(iv)

Read more: http://www.nasdaq.com/aspx/company-news-story.aspx?storyid=2…

Scheint nicht schlecht.

Gruß Oberländler

[Oberlaendler]

Antwort auf Beitrag Nr.: 40.116.706 von Oberlaendler am 08.09.10 11:30:20

PS: Mit freundlichem Dank an ipollit

[starwarrior03]

Hab ne Seite gefunden mit Übersicht -> Biotech/Pharma - Mergers and Acquisitions (World)..

http://www.biospace.com/news_subject_all_results.aspx?Catago…

Grüße..

[RichyBerlin]

Reata scores $450M in quick cash from Abbott pact
September 23, 2010 — 9:34am ET | By John Carroll

Irving, TX-based Reata Pharmaceuticals snared a treasure trove of $450 million in upfront and near-term cash from Abbott Labs in exchange for the ex-U.S. licensing rights to the mid-stage chronic kidney disease drug bardoxolone. The pact, which also excludes certain Asian markets, gives Abbott an equity stake in Reata along with licensing rights to other compounds in the Reata pipeline. And Reata stands to gain additional unspecified milestones plus royalties on any approved product.

It's a transformational deal for the Texas biotech. Reata was inspired by the scientific work undertaken by Mike Sporn at Dartmouth Medical School and originally set out to study the effect of bardoxolone on cancer. But in one cancer study researchers saw a big improvement in renal function among all renal cancer subjects. Arrested progression of chronic kidney disease or recovered kidney function was a provocative finding, CEO Huff told FierceBiotech earlier this year. So Reata mounted two Phase IIa trials for CKD in 2008. Those studies wrapped last year.

"This partnership allows us to meet our strategic goal of establishing our own commercial presence in the U.S. and building a sustainable, fully integrated pharmaceutical company," said Huff in a statement today.

"Early clinical studies suggest that bardoxolone could be a significant improvement to the current standard of care for CKD and possibly prevent patients from progressing to the later stages of the disease and dialysis," said John Leonard, senior vice president, pharmaceuticals, research and development, Abbott. "This agreement builds on Abbott's existing experience in renal care, while adding a promising compound to our later-stage pipeline."
http://www.fiercebiotech.com/story/reata-scores-450m-quick-c…

[RichyBerlin]

Antwort auf Beitrag Nr.: 38.447.924 von RichyBerlin am 24.11.09 19:52:06

Erweiterung des vorhandenen Deals!;

Clovis extends deal-making spree with $206M Asian pact
By John Carroll

Flush with cash from its $146 million A round last year, Clovis Oncology is ramping up a cancer drug pact it has with Norway's Clavis Pharma, adding $10 million in an upfront fee and $195M in potential regulatory and sales milestones in exchange for widening its commercial rights to a mid-stage pancreatic cancer drug. The deal extension expands its rights from the Americas and Europe to include Asia and the rest of the world.

Clovis and Clavis originally tied the knot last fall in a $380 million development and commercialization deal covering CP-4126, a lipid-conjugated form of the anti-cancer drug gemcitabine.

"We have established a strong collaboration with Clavis and believe this allows us to develop the drug consistently in Japan, China and additional Asian and international markets," said Clovis CEO Patrick Mahaffy. "We are already planning the development of our preclinical lung cancer compound in Asia so this expansion of our agreement with Clavis is also highly complementary to our global development and commercialization strategy."

The deal extension will put $586 million on the line for the one drug. But Clovis has been inking a number of deals, including one with Avila Therapeutics, as it pursues its plan to in-license a slate of cancer programs and build a biotech company around them. Mahaffey and several of his colleagues at Clovis were all engaged at Pharmion, a developer they sold for $2.9 billion.
http://www.fiercebiotech.com/story/clovis-extends-deal-makin…

[RichyBerlin]

Sanofi, Avila ink $800M oncology drug development pact
December 20, 2010 — 8:20am ET | By Maureen Martino

The dealmaking machine that is Sanofi-Aventis ($SNY) is at it again, signing an oncology drug pact worth $40 million up front and up to $154 million in milestone payments per program. Overall, the deal is valued at $800 million. Avila was founded in 2006 and already has 28 employees. And CEO Katrine Bosley, who was named one of the top 10 most influential women in biotech, tells FierceBiotech that the company plans to expand its ranks in the coming months.

Avila, which has already landed pacts with Clovis Oncology, Novartis and the Leukemia and Lymphoma Society, will use its Avilomics platform to help Sanofi design targeted covalent drugs for six signaling proteins that are critical in tumor cells. Covalent drugs are small molecules that forms a permanent bond to a disease target and silences that target. According to a statement, the targets are difficult to reach using traditional pharmaceuticals but could be susceptible to Avila's targeted covalent drug technology...

http://www.fiercebiotech.com/story/sanofi-avila-ink-800m-onc…

[Oberlaendler]

Amgen bets $1B on BioVex's dual-mechanism cancer therapy
January 25, 2011 — 8:30am ET | By John Carroll

In a bold late-stage gamble, Amgen has agreed to pay $425 million in cash to license a promising cancer vaccine from Woburn, MA-based BioVex, a 2009 Fierce 15 company which migrated to the U.S. several years ago in search of better VC relations. And Amgen promised another $575 million in milestones, offering up to a billion dollars in total to capture new therapies that use two fists to punch against cancer.

OncoVex has a dual mechanism. It's an oncolytic--using a cancer-destroying virus modified from a cold sore virus designed to replicate in solid tumors, triggering cancer cell death--as well as a vaccine, spurring the immune system to go in and tackle the cancer as well. And the technology also has applications that Amgen could use with its other cancer-related therapies. The size of the upfront payment, increasingly rare these days, is an indication of just how close BioVex is to producing pivotal data.

"It's a call option on a late-stage, potential blockbuster drug for Amgen," Michael Yee, an analyst with RBC Capital markets, told Bloomberg. And Bloomberg noted that the deal may well signal Amgen's intention to strike more pacts focused on tumor treatments.

OncoVex is now in Phase III for metastatic melanoma as well as head and neck cancer. In a small mid-stage study the therapy demonstrated significant anti-tumor results that need to be reflected in the late-stage data. The biotech also has a second program focused on genital herpes.

Read more: Amgen bets $1B on BioVex's dual-mechanism cancer therapy - FierceBiotech http://www.fiercebiotech.com/story/amgen-bets-1b-biovexs-dua…

Oberländler

[RichyBerlin]

Aveo inks $1.4B cancer drug deal, blueprints rapid expansion
By John Carroll

Aveo Pharmaceuticals ($AVEO) has landed a rich, $1.4 billion development and commercialization pact with Astellas for its late-stage VEGF inhibitor tivozanib. Now in a Phase III head-to-head study comparing the drug to Nexavar, Astellas will spearhead the commercialization work for tivozanib in Europe, leaving Aveo in charge in the U.S.

In exchange for the worldwide pact--excluding Asia, where Kyowa Hakko Kirin has already taken the lead--Aveo gets $125 million covering the upfront fee and R&D costs along with the promise for as much as $1.3 billion more in milestones. That includes $575 million in clinical and regulatory milestones and more than $780 million in commercial milestones.

For Aveo, the deal for tivozanib--which targets all three VEGF receptors--marks a major turning point. The pact comes as the developer is ramping up its Cambridge operations. CEO Tuan Ha-Ngoc tells FierceBiotech this morning that the company has just signed off on a lease for a third building neighboring its current headquarters. And Aveo plans to beef up its work force from about 150 now to some 220 at the end of this year. By the end of 2012, he says, the workforce could swell to some 300 staffers as the biotech shifts gears and launches a commercialization program--provided it can win an FDA approval. And Aveo plans to speed up its development work for other tumor types, particularly for breast and colorectal cancer...

http://www.fiercebiotech.com/story/aveo-nabs-14b-deal-astell…

[RichyBerlin]

Präklinik!

Array adds $713M cancer drug pact with Genentech to deal roster
August 9, 2011 — 8:29am ET | By John Carroll

Array BioPharma ($ARRY) has added another high-profile pact to its roster of big-name collaborations. Genentech has stepped in with an upfront payment of $28 million and a promise of up to $685 million in milestones so it can snag the rights to develop ARRY-575, a preclinical ChK-1 program that will be combined with a similar program of Genentech's and pushed into Phase I.

Genentech plans to match ARRY-575 with another Phase I compound, RG7602 or GDC-0475. Genentech will be responsible for the development costs and is also committed to a double-digit royalty stream on the early-stage program...

http://www.fiercebiotech.com/story/array-adds-713m-cancer-dr…

[RichyBerlin]

Nicht Onkologie, aber Impfstoff-Deals betreffen uns ja genauso;
Und der hier ist wirklich heftig.

Curevac Tübingen (eine von den Hopp/Bohlen-Firmen) & Sanofi-Pasteur
http://www.curevac.de/

"...Für jeden einzelnen Impfstoffkandidaten kann Curevac bis zu 101,5 Millionen Euro Vorauszahlungen sowie Forschungs- und Entwicklungsgelder abrufen. Handelt es sich um einen Krankheitserreger der sowohl vorbeugend als auch therapeutisch bekämpft wird, erhöht sich die Summe auf maximal 150,5 Millionen Euro. Hinzu kommen Lizenzgebühren bei Verkäufen von Impfstoffen, die auf der RNA-Technologie basieren..."

Das Ganze mit 33Mio.$ unterstützt vom amerikanischen DARPA
http://www.transkript.de/wirtschaft/wirtschaftsartikel/?tx_t…
"..Finanziert wird dieses von der amerikanischen Defense Advanced Research Projects Agency (DARPA). Diese Behörde des US-Verteidigungsministeriums, die unter anderem Wegbereiter des Internet und des Global Positioning Systems (GPS) war, sichert sich mit der Unterstützung von Grundlagenforschung den Zugriff auf innovative Technologien. Für die Finanzierung in Höhe von 33,1 Millionen Dollar (24 Millionen Euro) erhält die DARPA Anrechte zur Nutzung der Technologie..."
--
Unsere Kooperation mit Sanofi ist ja 2006/2007 im Sande verlaufen, soweit ich weiss
Kommentare bitte wie immer im normalen Thread. Danke

[RichyBerlin]

Fast-growing Forma grabs $815M cancer discovery deal with Boehringer
January 5, 2012 — 8:44am ET | By John Carroll

http://www.fiercebiotech.com/story/fast-growing-forma-grabs-…

Forma Therapeutics has nabbed an $815 million deal--$65 million of that in an upfront payment and the rest in pre-commercial milestones--to direct its growing drug discovery engine to new small molecule cancer therapeutics for Boehringer Ingelheim.

The pact marks another coup for Forma, a 2011 Fierce 15 company which has built up an extensive R&D operation designed to serve up new programs to a hungry set of biopharma companies around the globe. In this case, Forma plans to focus on multiple oncology targets over a four-year period. And they've set out to crack some tough cancer cases.

[RichyBerlin]

und nochmal Forma, wie vor ein paar Tagen (s.Posting vorher)

Forma scores another Big Pharma deal in $700M J&J cancer pact
January 10, 2012 — 9:43am ET | By John Carroll

Just days after inking an $815 million cancer drug discovery pact with Boehringer Ingelheim, Forma Therapeutics agreed to put its fast-growing small molecule ops to work for J&J's Janssen in a $700 million deal. This new pact, which focuses on tumor metabolism, also allows Forma to hang on to the North American commercial rights on one of the programs it develops--adding some long-term upside for the biotech. The announcement did not reveal how much Janssen is paying upfront...
http://www.fiercebiotech.com/story/forma-scores-another-big-…

[borsalin]

http://www.deraktionaer.de/aktien-usa/biotech-uebernahmewahn…

Amgen wird den Micromet-Aktionären elf Dollar je Aktie zahlen. Damit beläuft sich das Transaktionsvolumen auf 1,15 Milliarden Dollar. Das Micromet-Management hat dem Deal bereits zugestimmt

[Steven-35]

hmmmm, Micronet war im Tief bei 0,85 Doller ( vor ca. 4 Jahren ) und jetzt Übernahme zu 11 Dollar. Naja,Medigene war kürzlich auch bei 0,85.............

[RichyBerlin]

Celgene snaps up Avila Therapeutics in $925M buyout
January 26, 2012 — 8:15am ET | By John Carroll

In less than five years Avila Therapeutics nailed down a reputation as an exciting developer of covalent drugs, with a lead Btk inhibitor for cancer garnering attention at a very early stage of development. Today it turned that excitement into a $925 million buyout deal with Celgene ($CELG), with $350 million of that coming in cash.

The jewel in Avila's crown is AVL-292, a Btk inhibitor now in Phase I. The dealmakers involved in the buyout snagged a $195 million commitment for milestones leading up to a potential approval for that program. And Celgene will add the Avilomics platform to its R&D division, with another $380 million in back-end payments for the progress of other drug candidates that spring off the platform.

The Bedford, MA-based biotech was named a Fierce 15 company back in 2010, not long after the company garnered its last venture round of $30 million. Avila has been recognized for its novel approach to protein silencing, with much of the attention centered on its lead therapy for B cell cancers. The developer also has two candidates for hepatitis C--AVL-181 and AVL-192 targeting the NS3 protein--believing that its ability to create better bonds can deliver a best-in-class drug for one of the world's hottest disease categories...
http://www.fiercebiotech.com/story/celgene-snaps-avila-thera…

(Avila, siehe auch Beiträge #39 und #48)

--

Steven-35, hier bitte nicht mehr kommentieren. Hier werden nur die Deals gesammelt.
Kommentare bitte im anderen Thread, thanx
http://www.wallstreet-online.de/diskussion/1141290-neustebei…

[RichyBerlin]

Threshold, Merck KGaA strike $525M licensing deal for promising cancer drug
February 3, 2012 — 6:56am ET | By John Carroll

The dealmakers at South San Francisco-based Threshold Pharmaceuticals ($THLD) have crafted a $525 million licensing pact with Merck KGaA covering its late-stage cancer drug TH-302. Threshold snagged a $25 million upfront, a promise of $35 million in near-term paydays and a $20 million reward if upcoming pancreatic cancer data come in positive. And the biotech holds on to co-promotion rights in the United States.

In its release, Threshold outlined a total of $280 million in regulatory and development milestones and $245 million in milestones based on sales.

"The addition of TH-302 to our pipeline provides an important opportunity in several different tumor types to expand our oncology development program," said Susan Jane Herbert, who's in charge of business development and strategy at Merck Serono. "Given the fact that pancreatic cancer is a very difficult to treat indication, successful Phase II results could represent important upside for our company."

Threshold is all about TH-302. The biotech has 8 clinical trials underway involving the treatment.

In addition to the Phase II pancreatic cancer study,...
http://www.fiercebiotech.com/story/threshold-merck-kgaa-stri…

[borsalin]

Wann endlich meldet ein deutsches Biotechunternehmen den nächsten längst fälligen Deal?

übrigens

http://www.finanznachrichten.de/nachrichten-2012-02/22625947…

Pharma hat immer früher ihre Fühler (Geld) in der Forschung drin
hier am Beispiel Forschung an der der Eidgenössischen Technischen Hochschule in Zürich

[RichyBerlin]

Dainippon bags Boston Biomedical and cancer stem cell tech in $2.6B buyout

February 29, 2012 — 7:35am ET | By John Carroll
Boston Biomedical's focus on targeting cancer stem cells has paid off. Japan's Dainippon Sumitomo has snapped up the biotech for $200 million down, $540 million in development milestones for its two clinical-stage programs and close to $1.9 billion in commercial milestones, provided the drugs can achieve mega-blockbuster status.

In exchange for the cash and the promise of biobucks to come, Dainippon gets BBI608 and BBI503 and a new subsidiary in the U.S. which will spearhead its expansion in the cancer drug R&D field. The pharma company boasts that the two drugs are "likely to become the first anticancer drugs in the world targeting cancer stem cells." BBI608 is being prepped for a Phase III clinical trial for colorectal cancer in North America and in Phase Ib and II clinical trials for various solid tumors. BBI503 is in Phase I clinical trial for patients with various advanced solid tumors in North America....
http://www.fiercebiotech.com/story/dainippon-bags-boston-bio…

---

Oral - RA :

Abbott's deal-team delivers $1.35B Galapagos RA pact
February 29, 2012 — 9:19am ET | By John Carroll

Still wheeling and dealing as it lays the foundation for an independent pharma operation, Abbott ($ABT) today revealed that it is paying Belgian biotech Galapagos $150 million upfront to license in a promising oral treatment for rheumatoid arthritis. And it will pony up an additional $200 million if Galapagos can deliver positive Phase II data, along with a billion dollars in potential milestones.
The object of Abbott's affection is GLPG0634, a JAK1 inhibitor that Galapagos has been developing for RA and other autoimmune diseases. The JAK, or Janus kinases, are a group of enzymes responsible for triggering autoimmune diseases.
"We are excited to continue the Phase II trials and expect to deliver to Abbott a complete Phase II package in 2014," .....
http://www.fiercebiotech.com/story/abbotts-deal-team-deliver…

[RichyBerlin]

Mersana snaps up $270M cancer drug deal with Endo Pharma
March 7, 2012 — 9:52am ET | By Ryan McBride

Mersana Therapeutics has scored its second major collaboration deal. Endo Pharmaceuticals ($ENDP) has tapped Mersana to create antibody-drug conjugates against an undisclosed cancer target. And like almost all biotech collaborations nowadays, this one is laden with lots of potential dollars that the industry calls "biobucks."

Endo has agreed to pony up a mystery upfront fee to Cambridge, MA-based Mersana and, if Endo elects to expand the collaboration from one target to three, it could end up paying Mersana more than $270 million in potential payments, according to Mersana's release. There's no specific asset revealed in the companies' announcement, but Mersana is expected to combine Endo's antibodies with its own proprietary Fleximer technology and linkers for arming the antibody drugs with anti-cancer toxins.

Venture-backed Mersana can now count Endo along with its earlier pharma collaborator, Teva Pharmaceutical ($TEVA). Endo and Teva have bought into the potential for Mersana's platform to offer a new generation of antibody-drug conjugates, which combine the ability of antibodies to home in on tumor targets with the killer punch of anti-cancer toxins into one drug...
http://www.fiercebiotech.com/story/mersana-snaps-270m-cancer…

[RichyBerlin]

Merck snags rights to Endocyte's ovarian cancer drug in $1B deal
April 16, 2012 | By John Carroll

Merck has scooped up worldwide rights to Endocyte's ($ECYT) late-stage ovarian cancer drug in a billion-dollar deal, paying $120 million upfront and committing up to $880 million in milestones. And West Lafayette, IN-based Endocyte will also get co-promotion rights and a split of U.S. profits while earning double-digit royalties in the rest of the world.

Investors liked the sound of big round numbers, bidding up Endocyte shares by 111% once the news hit.

Merck ($MRK) says the drug--Vintafolide, or EC145--matches the profile of what it's looking for in a cancer drug, highlighting Endocyte's development of a companion diagnostic to identify patients most likely to respond to the treatment.

http://www.fiercebiotech.com/story/merck-snags-rights-endocy…

[borsalin]

http://www.finanznachrichten.de/nachrichten-2012-04/23321684…

Die Transaktion soll im zweiten oder dritten Quartal 2012 abgeschlossen werden. AstraZeneca zahlt 32 Dollar je Ardea-Aktie, das ist ein Prämie von über 50 Prozent auf den Schlusskurs vom Freitag.

[RichyBerlin]

Hier mal eine interessante Dealvariante von Abbott.

Abbott hits the sweet spot, pays $110M cash for PhIIb drug
May 3, 2012 | By John Carroll

...Abbott Laboratories ($ABT) has snagged Action Pharma's Phase IIb program for acute kidney injury with a one-time payment of $110 million in cash...

...The deal is unusual among biopharma partnerships. Abbott gets all rights for the lump sum payment, with no milestones or royalties due. And Action, a Danish biotech, gets the cash without risking a clinical setback. Zealand Pharma, meanwhile, gets $11 million for its stake in the program, along with the rights to a low, single-digit royalty...
http://www.fiercebiotech.com/story/abbott-hits-sweet-spot-pa…

[RichyBerlin]

Baxter and Onconova ink $500M-plus licensing pact for PhIII cancer drug
September 19, 2012 | By Ryan McBride

Onconova Therapeutics has scored a major partnership deal with Baxter International ($BAX), which has ponied up $50 million upfront and committed $515 million in potential milestones for European market rights to Onconova's anti-cancer drug rigosertib now in late-stage development for rare blood cancers and a Phase II/III trial for patients with pancreatic cancer...
http://www.fiercebiotech.com/story/baxter-and-onconova-ink-5…